Watchlists Portfolios Alerts Pricing Sign in Get started

Menu

Market-Moving News for December 19th

Benzinga Newsdesk Dec 19, 2023 2 years ago

MoversTrading Ideas

CGEN: 240% | Compugen Says It Will Be Eligible To Receive $10M Milestone Payment Upon Dosing Of First Patient In AstraZeneca Phase 3 Rilvegostomig Trial In Biliary Tract Cancer IFBD: 152% | Infobird

CGEN: 240% | Compugen Says It Will Be Eligible To Receive $10M Milestone Payment Upon Dosing Of First Patient In AstraZeneca Phase 3 Rilvegostomig Trial In Biliary Tract Cancer

IFBD: 152% | Infobird Inks New Business Cooperation In Software Development Of Information Technology System

ALDX: 42% | Aldeyra Therapeutics' Phase 2 Trial Of ADX-629 For Atopic Dermatitis Shows Statistically Significant And Clinically Relevant Improvement In Investigator-assessed And Patient-reported Outcomes Across Different Physiological And Psychosocial Assessments

Read the original